Literature DB >> 19838507

Hyperglycemia in pediatric head trauma patients: a cross-sectional study.

José Roberto Tude Melo1, Rodolfo Casimiro Reis, Laudenor Pereira Lemos, Henrique Miguel Santos Coelho, Carlos Eduardo Romeu de Almeida, Jamary Oliveira-Filho.   

Abstract

OBJECTIVE: To verify the prevalence of acute hyperglycemia in children with head trauma stratified by the Glasgow coma scale (GCS).
METHOD: A prospective cross-sectional study carried out with information from medical records of pediatric patients presenting with head injury in the emergency room of a referral emergency hospital during a one year period. We considered the cut-off value of 150 mg/dL to define hyperglycemia.
RESULTS: A total of 340 children were included and 60 (17.6%) had admission hyperglycemia. Hyperglycemia was present in 9% of mild head trauma cases; 30.4% of those with moderate head trauma and 49% of severe head trauma. We observed that among children with higher blood glucose levels, 85% had abnormal findings on cranial computed tomography scans.
CONCLUSION: Hyperglycemia was more prevalent in patients with severe head trauma (GCS <8), regardless if they had or not multiple traumas and in children with abnormal findings on head computed tomography scans.

Entities:  

Mesh:

Year:  2009        PMID: 19838507     DOI: 10.1590/s0004-282x2009000500004

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  2 in total

1.  Association of persistent hyperglycemia with outcome of severe traumatic brain injury in pediatric population.

Authors:  Seyed Mohammad Seyed Saadat; Elham Bidabadi; Seyedeh Nazanin Seyed Saadat; Mehryar Mashouf; Fatemeh Salamat; Shahrokh Yousefzadeh
Journal:  Childs Nerv Syst       Date:  2012-04-20       Impact factor: 1.475

2.  Association between Hyperglycaemia with Neurological Outcomes Following Severe Head Trauma.

Authors:  Javaher Khajavikhan; Aminolah Vasigh; Taleb Kokhazade; Ali Khani
Journal:  J Clin Diagn Res       Date:  2016-04-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.